非ホジキンリンパ腫患者を対象としたJNJ-95566692の研究
B細胞非ホジキンリンパ腫(NHL)における新規CD79bxCD20xCD3三特異性抗体の第1相、初回ヒト試験
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
研究場所
-
-
-
Clayton、オーストラリア、3168
- 募集
- Monash Medical Centre
-
Melbourne、オーストラリア、3000
- 募集
- Peter MacCallum Cancer Centre
-
North Ryde、オーストラリア、2109
- 募集
- Macquarie University Hospital
-
Randwick、オーストラリア、2031
- 募集
- Scientia Clinical Research
-
-
-
-
-
Barcelona、スペイン、8036
- 募集
- Hosp. Clinic de Barcelona
-
Barcelona、スペイン、08035
- 募集
- Hosp Univ Vall D Hebron
-
Madrid、スペイン、28041
- 募集
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28040
- 募集
- Hosp Univ Fund Jimenez Diaz
-
Madrid、スペイン、28050
- 募集
- Hosp Univ Hm Sanchinarro
-
-
-
-
-
Ankara、トルコ(Türkiye)、06200
- 募集
- SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi
-
Ankara、トルコ(Türkiye)、06620
- 募集
- Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
-
Antalya、トルコ(Türkiye)、07025
- 募集
- Memorial Antalya Hastanesi Faz 1 Klinik Arastirma Merkezi
-
Istanbul、トルコ(Türkiye)、34010
- 募集
- Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
-
-
-
-
-
Lille、フランス、59000
- 募集
- Hopital Claude Huriez
-
Paris、フランス、75013
- 募集
- CHU Pitie Salpetriere
-
Pierre-Bénite、フランス、69495
- 募集
- CHU Lyon Sud
-
Toulouse、フランス、31100
- 募集
- Institut Universitaire du Cancer Toulouse Oncopole
-
-
-
-
-
Edegem、ベルギー、2650
- 募集
- UZ Antwerpen
-
Liège、ベルギー、4000
- 募集
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- B-cell non-Hodgkin lymphoid malignancies (NHL) according to World Health Organization (WHO) 2022 and no other approved therapies available that would be more appropriate in the investigator's judgment. -Histologic documentation of the following large B-cell lymphomas: -diffuse large B-cell lymphoma not otherwise specified (NOS), -T-cell/histiocyte-rich large B-cell lymphoma, -diffuse large B-cell lymphoma/high grade B-cell lymphoma with MYC and BCL2 rearrangements, -large B-cell lymphoma with IRF4 rearrangement, -high grade B-cell lymphoma with 11q aberrations, -Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma, -diffuse large B-cell lymphoma associated with chronic inflammation, -primary large B-cell lymphoma of immune privileged sites, -primary cutaneous diffuse large B-cell lymphoma-leg type , -primary mediastinal large B-cell lymphoma, -high-grade B-cell lymphoma NOS, -transformations of indolent B-cell lymphoma (For US sites). -Other B-cell NHL may be enrolled based on emerging data in specific cohorts as stipulated by study evaluation team (SET)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Participants must have measurable disease as defined by the disease criteria (Lugano criteria)
- While on study treatment and for 3 months after the last dose of study treatment, a participant must: not breastfeed or become pregnant; not donate gametes (that is, eggs or sperm) or freeze for future use for the purposes of assisted reproduction; and wear an external condom; -Participants of childbearing potential must have a negative highly sensitive (for example, beta [β]-human chorionic gonadotropin) pregnancy test at screening and within 24 hours before the first dose of study treatment and agree to further pregnancy tests, -For Arm E ONLY: Practice 2 methods of reliable birth control simultaneously, including 1 highly effective form of contraception and 1 additional effective contraceptive method., -Participants on Arms C-G should also follow the pregnancy and contraception restrictions in the respective local corresponding product label
Exclusion Criteria:
- Known active central nervous system involvement (CNS) or leptomeningeal involvement
- Prior solid-organ transplantation
- Malignancy diagnosis other than the disease under study within 1 year prior to the first dose of the study treatment; exceptions are squamous and basal cell carcinoma of the skin, carcinoma in situ of the cervix and any malignancy that is considered cured or has minimal risk of recurrence within 1 year of first dose of the study treatment in the opinion of both the investigator and sponsor's medical monitor
- Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (for example, methotrexate or tacrolimus) within 3 months prior to first dose of study treatment
- Toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1 (except alopecia, vitiligo, peripheral neuropathy, or Grade <=2 endocrinopathies that are stable on hormone replacement)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A: JNJ-95566692
Participants will receive escalating doses of JNJ-95566692 in Part 1 (Dose escalation) to determine the putative recommended Phase 2 doses (RP2D[s]) and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 at the putative RP2D(s) determined in Part 1 to further characterize safety, PK (pharmacokinetic), pharmacodynamic (PD) and clinical activity. |
JNJ-95566692 will be administered subcutaneously. |
|
実験的:Arm B: JNJ-95566692 in combination with JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 in combination with JNJ-87801493 in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 in combination with JNJ-87801493 at the putative RP2D(s) determined in Part 1 to further characterize safety, PK, PD and clinical activity. |
JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. |
|
実験的:Arm C: JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493
Participants will receive escalating doses for JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. Loncastuximab tesirine will be administered intervenously. |
|
実験的:Arm D: JNJ-95566692 and R-GemOx with or without JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 and R-GemOx (rituximab, gemcitabine, oxaliplatin) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and R-GemOx with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. Rituximab will be administered intravenously and may be administered subcutaneously after the first administration. Gemcitabine will be administered intravenously. Oxaliplatin will be administered intravenously. |
|
実験的:Arm E: JNJ-95566692 and lenalidomide with or without JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 and lenalidomide with or without JNJ-87801493 in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and lenalidomide with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
Lenalidomide will be administered orally. JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. |
|
実験的:Arm F: JNJ-95566692 and R-CHOP with or without JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and R-CHOP with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
Cyclophosphamide will be administered intravenously. Prednisone will be administered orally. JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. Rituximab will be administered intravenously and may be administered subcutaneously after the first administration. Doxorubicin will be administered intravenously. Vincristine will be administered intravenously. |
|
実験的:Arm G: JNJ-95566692 and Pola-R-CHP with or without JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 and Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and Pola-R-CHP with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
Cyclophosphamide will be administered intravenously. Prednisone will be administered orally. JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. Rituximab will be administered intravenously and may be administered subcutaneously after the first administration. Doxorubicin will be administered intravenously. Polatuzumab vedotin will be administered intravenously. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1 and 2: Number of Participants with Adverse Events (AEs) And Serious Adverse Events (SAEs) by Severity
時間枠:Approximately 2 years and 8 months
|
An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational product and it does not necessarily have a causal relationship with the investigational product. Severity for AEs will be specified as per: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grades which are Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (potentially life-threatening) and Grade 5 (death related to adverse event). SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. |
Approximately 2 years and 8 months
|
|
Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)
時間枠:Approximately 2 years and 8 months
|
Number of participants with DLTs for JNJ-95566692 (arm A), in combination with JNJ-87801493 (arm B) and in arms C to G will be reported. The DLTs are drug-related toxicities and are defined as any of the following: fatal toxicity, high grade non-hematologic toxicity, or hematologic toxicity. |
Approximately 2 years and 8 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Serum Concentration for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
時間枠:Approximately 2 years and 8 months
|
Serum concentration for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be assessed using a validated assay method. |
Approximately 2 years and 8 months
|
|
Area Under the Curve During a Dosing Interval (AUCtau) in JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
時間枠:Approximately 2 years and 8 months
|
AUC tau is defined as area under the serum concentration-time curve during a dosing interval (tau). |
Approximately 2 years and 8 months
|
|
Maximum Serum Concentration (Cmax) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
時間枠:Approximately 2 years and 8 months
|
Cmax for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Minimum Serum Concentration (Cmin) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
時間枠:Approximately 2 years and 8 months
|
Cmin for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Area Under the Curve (AUC[0-t]) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
時間枠:Approximately 2 years and 8 months
|
AUC(0-t) for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Half-life (t1/2) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
時間枠:Approximately 2 years and 8 months
|
Half-life (t1/2) for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Time to Reach Cmax (Tmax) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
時間枠:Approximately 2 years and 8 months
|
Tmax is the time to reach maximum observed serum concentration for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Apparent Total Body Clearance (CL/F) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
時間枠:Approximately 2 years and 8 months
|
CL/F for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Apparent Volume of Distribution (V/F) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
時間枠:Approximately 2 years and 8 months
|
V/F for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Number of Participants with Anti-JNJ-95566692 Antibodies in Arms A to G
時間枠:Approximately 2 years and 8 months
|
Participants with presence of antibodies binding to JNJ-95566692 in arm A to G will be reported. |
Approximately 2 years and 8 months
|
|
Number of Participants with Anti-JNJ-87801493 Antibodies in Arms B to G
時間枠:Approximately 2 years and 8 months
|
Participants with presence of antibodies binding to JNJ-87801493 in arm B to G (as appropriate) will be reported. |
Approximately 2 years and 8 months
|
|
Part 2: Overall Response for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
時間枠:Approximately 2 years and 8 months
|
Overall response is defined as a best response of partial response (PR) or better as assessed by the investigator according to standard response criteria per Lugano. |
Approximately 2 years and 8 months
|
|
Part 2: Complete Response (CR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
時間枠:Approximately 2 years and 8 months
|
Complete response (CR) is defined as a best response of CR as assessed by the investigator according to standard response criteria per Lugano. |
Approximately 2 years and 8 months
|
|
Part 2: Time to Response (TTR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
時間枠:Approximately 2 years and 8 months
|
TTR is defined for participants who achieved a response of PR or better as the time from the first dose of study treatment to the first response of PR or better. |
Approximately 2 years and 8 months
|
|
Part 2: Duration of Response (DOR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
時間枠:Approximately 2 years and 8 months
|
DOR is defined for participants who achieved a response of PR or better as the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease, initiation of a new systemic anti-cancer therapy or death. |
Approximately 2 years and 8 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 免疫系疾患
- 組織型別の新生物
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫
- ヘミックおよびリンパ疾患
- リンパ腫、非ホジキン
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 炭化水素
- 炭化水素、周期的
- 炭水化物
- カルボン酸
- アルカロイド
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- グリコシド
- ピペリジン
- インドール
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 調整錯体
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- 妊娠
- 妊娠
- ステロイド
- 融合リング化合物
- ホスホルアミドマスタード
- 窒素マスタード化合物
- マスタード化合物
- 炭化水素、ハロゲン化
- ホスホラミド
- 有機リン化合物
- 妊娠した
- ヴィンカアルカロイド
- セコロガニントリプタミンアルカロイド
- インドールアルカロイド
- インドリジジン
- インドリジン
- アントラサイクリン
- ナフテセン
- アミノグリコシド
- 抗体、モノクローナル、マウス由来
- ダウノルビシン
- フタリミド
- フタル酸
- 酸、炭素環
- ピペリドン
- イソインドール
- レナリドミド
- オキサリプラチン
- リツキシマブ
- ゲムシタビン
- プレドニン
- シクロホスファミド
- ドキソルビシン
- ビンクリスチン
- ポラツマブヴェドチン
- Loncastuximabテシリン
その他の研究ID番号
- 95566692LYM1001
- 95566692LYM1001 (その他の識別子:Janssen Research & Development, LLC)
- 2025-523297-16-00 (レジストリ識別子:EUCT number)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。